Lurbinectedin
Small molecule
Evidence outlook
Approved: Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
LAGOON NCT05153239 · Relapsed Small Cell Lung Cancer Registry: NCT05153239 | 3 | Overall survival (From the date of randomization to the date of death or last contact, up to 39 months) 2026-04-10 | Median OS 8.7 months (lurbinectedin alone, HR 1.190) and 10.9 months (with irinotecan, HR 0.902) vs 10.7 months for topotecan/irinotecan; primary OS endpoint missed. | not yet graded | link ↗ |
View 3 more trials
ATLANTIS NCT02566993 · Small-cell Lung Cancer This was a large randomized active-controlled trial with 307 patients in the lurbinectedin/doxorubicin arm and 306 in the control arm, but it was open-label rather than blinded. Its hard clinical primary endpoint, overall survival, was not significantly improved, so the evidence is meaningful but does not establish a favorable primary-treatment effect. Registry: NCT02566993 | 3 | Overall Survival (OS) (Every three months up to death or study termination, a period of approximately 3.5 years) 2020-02-24 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
IMforte NCT05091567 · Small Cell Lung Cancer IMforte was a randomized, open-label Phase 3 trial in 483 adults with extensive-stage small cell lung cancer whose disease had not progressed after four cycles of atezolizumab, carboplatin and etoposide. Patients received maintenance lurbinectedin with atezolizumab or atezolizumab alone. Both registered primary endpoints were met: overall survival improved (HR 0.73, 95% CI 0.57 to 0.95, p=0.0174, below the allocated alpha of 0.0313) and independently assessed progression-free survival improved (HR 0.54, 95% CI 0.43 to 0.67, p<0.0001). The open-label design is a limit for the progression endpoint, which was assessed by independent review. Source: the ZEPZELCA US label, section 14.1. Registry: NCT05091567 | 3 | Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS) (Up to 26 months); Randomized Phase: Overall Survival (OS) (Up to 26 months) 2024-07-29 | Two registered primaries in the randomized phase, lurbinectedin plus atezolizumab (n=242) vs atezolizumab alone (n=241): overall survival median 13.2 vs 10.6 months, HR 0.73 (95% CI 0.57 to 0.95), p=0.0174 against an allocated two-sided alpha of 0.0313 at the interim analysis; IRF-assessed progression-free survival median 5.4 vs 2.1 months, HR 0.54 (95% CI 0.43 to 0.67), p<0.0001 (ZEPZELCA US label, section 14.1, Table 7). | not yet graded | link ↗ |
NCT02454972 NCT02454972 · Small Cell Lung Cancer Registry: NCT02454972 | 2 | Overall Response Rate (ORR) (From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)); Response by Investigator Assessment (From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)) 2020-09-18 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (7)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lurbinectedin: this drug | Approved | Small molecule | Alkylating Drug | Partial signal | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tarlatamab | Approved | Multispecific antibody | DLL3 and CD3 | Partial signal | NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08). NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025). | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-706 | Phase 3 | Antibody–drug conjugate | SEZ6 | not yet graded | No reviewed efficacy summary in this indication | |
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| AL8326 | Phase 3 | Small molecule | Aurora B / FGFR / VEGFR (multi-kinase) | Weak signal | NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022) | |
| Atigotatug | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Gocatamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Obrixtamig | Phase 3 | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Pumitamig | Phase 3 | Multispecific antibody | PD-L1 and VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Risvutatug Rezetecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Serplulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tislelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alisertib | Phase 2 | Small molecule | Aurora kinase A (AURKA) | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986525 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| DJI136 | Phase 1/2 | Cell therapy | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Quaratusugene Ozeplasmid (Reqorsa) | Phase 1/2 | Gene therapy / editing | TUSC2 (tumor suppressor gene replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(20 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lurbinectedin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (5)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
September 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
2029 (5)
April 2029 (2)
August 2029 (2)
October 2029 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent